Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: Serum sCD26 levels in patients with CTCL and psoriasis (162.1 ± 80.2 ng/mL and 125.4 ± 82.1 ng/mL respectively) were significantly lower than those of healthy controls (392.6 ± 198.7 ng/mL; P < 0.01 and 0.01 respectively). In patients with CTCL, serum sCD26 levels of patients with advanced stage were 135.0 ± 51.5 ng/mL and they were significantly lower than those with early stage (193.1 ± 96.0 ng/mL; P < 0.05). When we used serum sCD26 and TARC levels for diagnostic criteria, sensitivity, specificity, positive predictive value and negative predictive value for AD, CTCL and psoriasis were 65.2-73.7%, 81.4-97.6%, 65.2-94.4%, and 81.4-88.9% respectively. CONCLUSION: Serum sCD26 levels, combined with serum TARC levels, are helpful in diagnosis of AD, CTCL and psoriasis.
|
Authors | T Miyagaki, M Sugaya, H Suga, S Morimura, M Kamata, H Ohmatsu, H Fujita, Y Asano, Y Tada, T Kadono, S Sato |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 27
Issue 1
Pg. 19-24
(Jan 2013)
ISSN: 1468-3083 [Electronic] England |
PMID | 22077186
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology. |
Chemical References |
- Biomarkers
- Chemokine CCL17
- Dipeptidyl Peptidase 4
|
Topics |
- Adult
- Biomarkers
(blood)
- Case-Control Studies
- Chemokine CCL17
(blood, metabolism)
- Dermatitis, Atopic
(blood, diagnosis, physiopathology)
- Dipeptidyl Peptidase 4
(blood, metabolism)
- Disease Progression
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Lymphoma, T-Cell, Cutaneous
(blood, diagnosis, physiopathology)
- Male
- Middle Aged
- Psoriasis
(blood, diagnosis, physiopathology)
- Reference Values
- Risk Assessment
- Sensitivity and Specificity
- Severity of Illness Index
- Solubility
|